Aristei C.,Radiation Oncology Section |
Falcinelli L.,Radiation Oncology Section |
Palumbo B.,Nuclear Medicine Section |
Tarducci R.,Perugia General Hospital
Expert Review of Anticancer Therapy | Year: 2010
This review analyzes PET images in radiotherapy treatment planning for lung cancer patients and discusses the most controversial current issues. Computed tomography images are commonly used to assess location and extension of target volumes and organs at risk in radiotherapy treatment planning. Although PET is more sensitive and specific, contouring on PET images is difficult because tumor margins are indistinct, due to heterogeneous 18fluorodeoxyglucose uptake distribution and limited spatial resolution. The best target delineation criteria have not yet been established. In non-small-cell lung cancer, PET appears to improve sparing of organs at risk and reduce the risk of toxicity; prescribed doses can be increased. Data are scarce on small-cell lung cancer. © 2010 Expert Reviews Ltd.
Katanyoo K.,Radiation Oncology Section |
Chantarasri A.,Bangkok University |
Chongtanakon M.,Radiation Oncology Section |
Rongsriyam K.,Radiation Oncology Section |
Tantivatana T.,Radiation Oncology Section
Asian Pacific Journal of Cancer Prevention | Year: 2011
Objective: To evaluate pretreatment levels of serum VEGF in locally advanced cervical cancer patients, and assess any association with clinocopathological parameters and response to radiotherapy. Methods: Patients with histologically proven and diagnosed locally advanced cervical cancer or stages IIB-IVA were included in this study. Blood serum was obtained by peripheral venous puncture about 24 hours before the beginning of radiotherapy. All patients were followed up at one and three month intervals from the last day of the complete treatment for evaluating the responses to radiotherapy. Results: Mean age of the 40 patients was 52.8±11.1 years. Sixty percent were in stage IIB and 90% had squamous cell carcinoma. The median pretreatment level of serum VEGF was 611.3 pg/ml (0.00-4,067.20 pg/ml). The pretreatment levels of serum VEGF did not correlate with stage (p=0.75), tumor histology (p=0.91), tumor size (p=0.46) or tumor characteristics (p=0.49). Almost all patients received concurrent chemoradiation as a curative treatment, with a complete response found in 94.9%. Values for patients who were completed response was rather lower than patients with persistent disease, but without statistical significance (581.4 pg/ml vs 759.6 pg/ml, p=0.37). Conclusion: Pretreatment levels of serum VEGF do not correlate with clinicopathological factors or response to radiation therapy.